author-photo

Michael K.K. Wong

University of Southern California

12

Papers

21

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

2017
Show All
- Source
- Cite
- Save
Citations (0)
Association of improved survival (OS) and tumor control (TC) with interleukin-2 (IL2) with development of immune-related events (IREs): Data from the PROCLAIMSM registry.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Extension of overall survival in patients with metastatic renal cell carcinoma who received HD IL-2 followed by targeted therapy and/or immune checkpoint blockade from the PROCLAIM registry.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Update on the overall survival of patients with metastatic melanoma treated with immune checkpoint blockade following initial treatment with HD IL-2.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract B140: Overall survival of metastatic melanoma patients treated with HD IL-2 followed by immune checkpoint blockade of the CTLA-4 or the PD-1 pathways: Analysis of data on the current use of HD IL-2

2016 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Impact of targeted therapy (TT) on survival of metastatic renal cell carcinoma (mRCC) patients treated with high dose interleukin-2 (HD IL-2): Analysis of the PROCLAIM HD IL-2 National Registry.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Overall survival of metastatic melanoma (mM) treated with high dose IL-2 (HD IL-2) followed by anti-CTLA4 (IPI) and/or anti-PD-1/PDL1 (aPD1) therapy: Analysis of the prospective cohort of the PROCLAIM national registry.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (7)